Migraine Treatment Market Scope, Share Analysis And Growth 2025

Drawing from trusted sources and expert analysis, this report helps businesses navigate the complex landscape of the migraine treatment industry.

What Is The Expected CAGR For The Migraine Treatment Market Through 2025?
The migraine treatment market size has grown strongly in recent years. It will grow from $3.18 billion in 2024 to $3.45 billion in 2025 at a compound annual growth rate (CAGR) of 8.4%. The growth in the historic period can be attributed to increased prevalence of migraines, increased healthcare expenditure, improved formulations of existing drugs, expansion of clinical research, development of novel therapies.

The migraine treatment market size is expected to see rapid growth in the next few years. It will grow to $5.21 billion in 2029 at a compound annual growth rate (CAGR) of 10.9%. The growth in the forecast period can be attributed to growing awareness and education, emergence of monoclonal antibodies, increasing focus on pediatric migraines, expansion of non-pharmacological interventions, global initiatives for migraine research. Major trends in the forecast period include advancements in therapeutic approaches, wearable devices and digital therapeutics, telemedicine and remote consultations, patient-centric care models, generic drug market growth, oral CGRP inhibitors.

Get your free sample today:
https://www.thebusinessresearchcompany.com/sample.aspx?id=8126&type=smp

Which Key Factors Will Influence Migraine Treatment Market Growth Over 2025-2034?
The prolonged screen exposure is expected to propel the growth of the migraine treatment market. Screen exposure refers to the amount of time individuals spend interacting with electronic screens, such as those on smartphones, tablets, computers, and televisions. Prolonged screen exposure is driven by factors such as increased remote work, online education, digital entertainment, and the growing reliance on technology for social interaction. Migraine treatment manages migraine symptoms triggered or worsened by extended screen time, including medications, lifestyle modifications, and the use of ergonomic practices to minimize strain and prevent attacks. For instance, in May 2024, according to the House of Commons Committee, a UK-based Parliament health agency, in 2021, children's screen time increased by 52% in 2022, with nearly 25% of children and young people showing smartphone usage patterns consistent with behavioral addiction. Therefore, the prolonged screen exposure is driving the growth of the migraine treatment market.

Comprehensive Segment-Wise Insights Into The Migraine Treatment Market
The migraine treatmentmarket covered in this report is segmented –

1) By Types: Episodic; Migraine With Aura; Chronic; Other Types
2) By Treatment: Acute Or Abortive Treatment; Preventive Or prophylactic Treatment; Non-Pharmacological Therapies And Devices
3) By End-User: Hospitals; Clinics; Homecare; Other End-users

Subsegments:
1) By Episodic: Frequent Episodic Migraine; Infrequent Episodic Migraine
2) By Migraine With Aura: Visual Aura; Sensory Aura; Speech Or Language Aura
3) By Chronic: Chronic Migraine Without Aura; Chronic Migraine With Aura
4) By Other Types: Hemiplegic Migraine; Retinal Migraine; Menstrual Migraine; Other Specific Types

Key Trends Driving Growth In The Migraine Treatment Market
Product innovations are the key trend gaining popularity in the migraine treatment market. Major companies operating in the market are introducing innovations such as liquid formulation to sustain their position in the market. For instance, in January 2022, BioDelivery Sciences International (BDSI), a US-based pharmaceutical company, launched Elyxyb (celecoxib oral solution), the acute treatment of migraines in adults, whether or not they experience aura. Its liquid formulation allows for rapid absorption in the small intestine, delivering faster relief compared to traditional tablets. This is especially beneficial for migraine sufferers who experience nausea or vomiting, as it eliminates the need to wait for a pill to dissolve. As the first and only FDA-approved ready-to-use oral solution for migraines, Elyxyb provides a more tolerable and efficient treatment option for managing the sudden, intense pain associated with migraines.

Analysis Of Key Players In Migraine Treatment Market
Major companies operating in the migraine treatment market are Pfizer Inc., Eli Lilly and Company, Amgen Inc., GlaxoSmithKline PLC, Novartis AG, Bayer AG, Allergan PLC, Abbott Laboratories, Allodynic Therapeutics LLC, AOBiome LLC, AstraZeneca PLC, Bausch Health Companies Inc., Boehringer Ingelheim International GmbH, Dr. Reddy's Laboratories Limited, Impel Pharmaceuticals Inc., AbbVie Inc., Alder BioPharmaceuticals Inc., Astellas Pharma Inc., Biohaven Pharmaceutical Holding Company Ltd., Bristol-Myers Squibb Company, Daiichi Sankyo Company Limited, Eisai Co. Ltd., Endo International PLC, Impax Laboratories Inc., Johnson & Johnson Inc., Lannett Company Inc., Lupin Limited, Merck & Co. Inc., Mylan N.V.

View the full migraine treatment market report here:
https://www.thebusinessresearchcompany.com/report/migraine-treatment-global-market-report

What Are The Key Regional Trends In The Migraine Treatment Market?
North America was the largest region in the migraine treatment market in 2024. The regions covered in the migraine treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Contact Us:

The Business Research Company

https://thebusinessresearchcompany.com/

Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267

Email: info@tbrc.info


Follow Us On:

LinkedIn: https://in.linkedin.com/company/the-business-research-company